Introduction
Healthy human adults generate about 2 million erythrocytes each second through a highly coordinated process starting with progenitor and multipotent hematopoietic stem cells [1] . The lifespan of circulating erythrocytes ends physiologically after more than 100 days due to erythrocyte senescence [2] . If erythrocytes experience damage prior to senescence, they may, however, enter suicidal death or eryptosis.
The process of eryptosis is characterized by cell membrane scrambling leading to breakdown of the cell membrane asymmetry and translocation of phosphatidylserine from the interior to the cell membrane surface [2-10]. The cell membrane scrambling is typically paralleled by erythrocyte shrinkage and by the formation of blebs on the erythrocyte surface. Eryptotic erythrocytes are rapidly cleared from circulating blood [2, 11] , as phosphatidylserine-exposing erythrocytes are bound primarily to respective receptors of splenic marginal zone macrophages and CD207
+ dendritic cells [11] , which engulf and degrade the injured erythrocytes [2] .
Phosphatidylserine at the surface of eryptotic erythrocytes further binds to endothelial cells, by interaction of phosphatidylserine with the CXC-motifchemokine 16/scavenger receptor (CXCL16/SRPSO) [2] . Eryptotic erythrocytes adhering to the endothelial cells in the interior surface of the vascular wall, in turn, interfere with microcirculation, thus, impeding normal blood flow to tissues [2] . Phosphatidylserine exposing eryptotic erythrocytes further bind to blood platelets and may, thus, trigger blood clotting and thrombosis [2] .
Eryptosis, erythropoiesis and the clinical relevance of anemia
Eryptosis aims to prevent hemolysis of defective erythrocytes, but may lead to anemia, if it is not outweighed by a matching stimulation of erythropoiesis [2] . Anemia is clinically defined as decreased hemoglobin, hematocrit level and/or a reduced erythrocyte count. Changes in these blood parameters may lead to severe hypoxia of different organs [12] and patients may present symptoms such as impaired cognitive performance, depression, cardiovascular complications, chest pain, indigestion, dizziness and exertional dyspnea [13] . According to epidemiological studies, approximately one-third of the whole world population suffers from some form of anemia [14] .
In cancer patients, anemia not only worsens fatigue but is also associated with shorter survival rates [15] . As a matter of fact, compelling evidence suggests that anemia can be considered as an independent prognostic factor for survival of patients suffering from cancer [16] . Cancer-associated anemia may even reduce acceptance and tolerance to anticancer therapy [17] as it may lead to hypoxia, thus, influencing tumor behavior [18] . Tumor hypoxia, by the same token, is itself linked with enhanced tumor aggressiveness [19] and both resistance to both chemotherapy and radiation therapy [20] . Similar to cancer, anemia in heart failure (HF) is also associated with a poor prognosis [21] and the occurrence of increased edema, enhanced levels of neurohormones, proinflammatory cytokines, C-reactive protein, lower blood pressure and a higher use of diuretics [22] . Not only in cancer and HF, but also in chronic kidney disease (CKD), the occurrence of anemia remains one of the many complications and is linked to a poor outcome. Anemia in CKD is associated with an impaired life quality, cardiovascular complications, disease progression, cognitive impairment, insomnia and higher mortality rates [23, 24] .
Erythropoiesis is a differentiation process, which generates erythrocytes from hematopoietic stem and progenitor cells [25] . A wide variety of clinical disorders may affect erythropoiesis. In b-thalassemia, for example, the anemia results due to an imbalance of a/b-globin chain synthesis leading to a shortened erythrocyte survival [26] . Remarkably, in several other conditions anemia prevails despite reticulocytosis, a process leading to the rapid differentiation of reticulocytes to mature erythrocytes. In the presence of normal erythrocyte counts in the blood stream, however, reticulocytosis may be an indicator of augmented eryptosis despite normal erythrocyte counts in the blood stream [27] . If reticulocytosis does not replenish the loss of erythrocytes, a clinically visible anemia ensues [28] . In order to maintain normal hemoglobin levels, arterial oxygenation in the blood stream is sensed by the kidney and the carotid body [29] . Consequently, the extent of erythropoiesis is adapted to meet the oxygen requirements of the organism [30] . Anemia may, thus, develop as a result of either a reduced generation, an augmented destruction by hemolysis, blood loss [30] or by enhanced eryptosis. Importantly, anemia is not the sole pathological consequence of accelerated eryptosis in vivo. Furthermore, eryptotic erythrocytes tend to adhere to thrombocytes and endothelial cells that leads to microcirculation impediment and contributes to the development of thrombosis [31] [32] [33] . Thrombocytes and endothelial cells express the surface receptor SR-PSOX, also known as CXC chemokine ligand CXCL16, that stimulates the interaction between the phosphatidylserine (PS)-exposing erythrocytes and endothelial cells [31] . Thrombospondin-1 and CD36, additional molecules expressed on endothelial cells may likewise be involved in the adherence of PS-exposing erythrocytes to endothelial cells [34, 35] . Not only endothelial cells, but also thrombocytes express CD36, which has been demonstrated to network with erythrocyte PS [36] . As several clinical conditions such as CKD [37] and HF [38] are accompanied by increased thrombophilia, the interplay between PS and CD36/CXCL16 could substantially contribute to thrombus development in these disorders.
Clinical treatment of anemia
Although anemia is associated with many untoward symptoms in a wide range of systemic conditions, its importance has been widely underestimated receiving suboptimal therapeutic attention [39] . According to the World Health Organization, anemia can be classified into mild (9.5-10.9 gÁdL À1 hemoglobin, grade 1), moderate (8.0-9.4 gÁdL
À1
, grade 2), severe (6.5-7.9 gÁdL À1 , grade 3) and life-threatening anemia (<6.5 gÁdL À1 , grade 4) [40] . Anemia can further be classified by extrapolating the amount of hemoglobin per erythrocyte (mean corpuscular hemoglobin concentration) and the erythrocyte size (mean corpuscular volume) [41] .
Other indicators that aid in the clinical diagnosis of anemia include plasma levels of ferritin, transferrin and transferrin saturation [42] . In clinical practice, therapeutic intervention has largely been limited to moderate and severe anemia, while milder forms of anemia have generally been overlooked [20] . When iron deficiency is not the underlying cause of anemia, hemoglobin level is mainly corrected by administration of erythropoiesis-stimulating agents (ESAs) and by erythrocyte transfusion [43] . ESAs activate the erythropoietin receptor (EpoR) leading to enhanced erythrocyte production in the bone marrow [44] . Commonly used ESAs are epoetin alpha, epoetin beta and darbepoetin alfa [45] . Both treatments are associated with benefits, but, on the flipside, carry several risks and their benefits, thus, being disputable. Although transfusion provides a rapid possibility of correcting hemoglobin level, its application is, however, associated with potential complications such as over-transfusion, transmission of infectious diseases, unsought transfusion reactions, alloimmunization, lung injury, iron overload, thrombosis and even shortened survival [46] [47] [48] . Remarkably, the use of ESAs obviates the need for erythrocyte transfusion [43] . Nevertheless, previous studies have reported enhanced tumor progression, cardiovascular complications, decreased survival rates and increased mortality rates linked with ESA treatment [49] .
In view of the undesired complications of erythrocyte transfusions and ESAs, it would be desirable to diminish anemia by targeting accelerated erythrocyte loss using pharmacological inhibitors of eryptosis. However, while such an approach is conceivable, it would additionally require the development of agents acting specifically on erythrocytes. In cancer patients, for instance, a more controlled-approach is advocated where inhibitors of eryptosis do not prevent the apoptosis of tumor cells nor interfere with cytostatic treatment of the patient. In cancer patients, correction of anemia by inhibition of eryptosis is expected to decrease erythropoietin release, a growth factor known to favor lymphangiogenesis and tumor angiogenesis [50] . Inhibition of eryptosis would further have the potential to reduce the risk of thromboembolic complications, which frequently occur in cancer, even without the use of ESAs [43] .
Correction of anemia in CKD is mainly carried out by iron supplementation and application of ESAs [24] . Erythropoietin and iron replacement, however, only partially reverse prevailing anemia, suggesting the role of additional mechanisms in CKD-related anemia. Anemia in CKD is often not normalized despite overcompensation of erythropoietin deficiency. Compelling evidence suggests that anemia in CKD is mainly the result of accelerated suicidal erythrocyte death [51] [52] [53] . Although erythropoietin inhibits erythrocyte cation channel activity [54] , its application in CKD is apparently not sufficient to fully compensate anemia. Inhibition of eryptosis by further pharmacological inhibitors would, thus, be desirable in that condition.
The importance of oxidative stress in eryptosis
Eryptosis may be induced by oxidative stress [2,55], which not only plays a crucial role in eryptosis-related pathophysiology in several diseases but also contributes to its stimulation by a wide spectrum of xenobiotics [55] [56] [57] [58] [59] [60] . Oxidative stress is defined as an augmented production and/or a diminished elimination of reactive oxygen species (ROS) affecting the major cellular components such as DNA, lipids and proteins. The balance between the removal and the production of cellular ROS is defined as the 'redox state' [61] . Pro-oxidative molecules are primarily produced in physiological conditions and play a decisive role in a variety of signaling pathways regulating cell migration, activation and proliferation. Free radicals are even considered to be beneficial in low amounts [62] as they serve in fighting against tumor proliferation, viruses and pathogens [63] . However, when produced in excess, they can be deleterious for the host cells as passing their unpaired electron leads to oxidation of various molecules and cellular components [64] . Generally, free radicals can be grouped into ROS, reactive nitrogen species (RNS) and reactive chlorine species (RCS) [65] . ROS are generated in various compartments including the cytoplasm, extracellular fluids (e.g., plasma), mitochondria, endosomes, peroxisomes, phagosomes and exosomes [66] . Most ROS are generated in the mitochondria by mechanisms involving the respiratory chain [67] . Different classes of ROS, such as hydroxyl radicals (OHÁ), superoxide (O À 2 ) or hydrogen peroxide (H 2 O 2 ), show different reactivities and half-life. The newly generated ROS are transported via vesicles and channels [68] .
Antioxidant defense mechanisms in erythrocytes
Erythrocytes are a prime target for oxidative stress due to their primary function as O 2 -carrying cells. In the circulating blood stream, erythrocytes are continuously exposed to ROS, for example, hydrogen peroxide and superoxide. Thus, these cells have established a sophisticated antioxidant defense system, which includes nonenzymatic antioxidants such as glutathione (GSH) [69] and enzymatic antioxidants including glutathione peroxidase (GPx) [70] , superoxide dismutase [71, 72] , catalase [71, 72] or peroxiredoxin 2 [73] . Oxidative stress may, thus, ensue when there is an imbalance between the generation of oxygen species and their elimination (Fig. 1) . Erythrocytes that are exposed to oxidative stress generate molecular signals that result in the activation of Ca 2+ permeable cation channel [74] , which results in Ca 2+ entry into the cells. Ca 2+ subsequently activates Ca 2+ -sensitive K + channels triggering cell shrinkage [75] and Ca 2+ -sensitive scrambling of the erythrocyte membrane [76] resulting in the exposure of phosphatidylserine at the erythrocyte surface [77] , typical signs of eryptosis.
The present review describes the cellular mechanisms regulating eryptosis as well as various clinical conditions associated with this phenomenon. Particular emphasis will be laid upon the mechanisms and clinical conditions involving oxidative stress. The reader is encouraged to consult previous reviews for further perspectives on this fundamental physiological mechanism [4, [78] [79] [80] [81] .
Signaling involved in the orchestration of eryptosis 
Oxidants
Oxidative stress in erythrocytes 
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The FEBS Journal 286 (2019) 826-854 ª 2018 Federation of European Biochemical Societies stimulated by platelet-activating factor (PAF), which, in turn, is generated by a phospholipase A 2 [84] . Oxidative stress, leukotrienes and a-lipoic acid are further partially effective by stimulation of caspases [2, 4] . Caspases activated by oxidative stress cleave the anion exchanger AE1 [85] and trigger the exposure of phosphatidylserine from the inner leaflet to the outer erythrocyte surface [86] . Activation of caspases is, however, not required for Ca 2+ entry and Ca 2+ -dependent phosphatidylserine exposure [87] . Moreover, oxidative stress stimulates Cl À channels in erythrocytes [88] that are necessary for cell shrinkage, a typical hallmark of eryptosis [87] . A detailed scheme of oxidative stress triggered eryptosis signaling is displayed in Fig. 2 . Signaling regulating eryptosis further involves the heterotrimeric G-protein subunit Ga i2 [89] . Several kinases have been shown to participate in the regulation of eryptosis. Pharmacological inhibition of protein kinase C or cyclin-dependent kinase 4 (CDK4) is followed by blunting of eryptosis following excessive erythrocyte shrinkage and oxidative stress [2, 90] . Exposure of erythrocytes to hyperosmotic shock activates the p38 mitogen-activated kinase via phosphorylation, which contributes to the stimulation of eryptosis [2, 91] . Full stimulation of eryptosis by oxidative stress or energy depletion further requires casein kinase 1a (CK1a) [92] . CK1a is, in turn, a powerful regulator of the nonselective cation channels permeable to Ca 2+ ions [93] . Energy depletion in addition activates Janus-activated kinase JAK3, which in turn triggers eryptosis [4] . Energy depletion further stimulates the energy sensing AMP-activated kinase (AMPK), which inhibits eryptosis [2] . Proteomic analysis of AMPK-deficient erythrocytes has revealed reduced levels of p21-activated kinase 2, which was demonstrated to influence erythrocyte survival [94] . Eryptosis is further inhibited by mitogen-and stressactivated kinase MSK1/2 and mice deficient in these enzymes display accelerated clearance of eryptotic erythrocytes contributing to a moderately enlarged spleen [95] . Stimulation of eryptosis by sorafenib and sunitinib points to inhibition of eryptosis by tyrosine kinases [96, 97] . In addition, eryptosis is inhibited by the cGMP-dependent protein kinase (cGKI) [98] . The cGKI is stimulated by nitric oxide (NO), which is accumulated in erythrocytes [2] . Similar to cGK1 and NO, dibutyryl-cGMP inhibits eryptosis [2] .
Eryptosis is additionally enhanced by genetic knockout of adenosine 5 0 -monophosphate deaminase (AMPD3) [99] . Eryptosis has also been shown to be regulated by regulatory small noncoding RNAs (ncRNAs) [100] .
Clinical conditions stimulating eryptosis by generation of oxidative stress
Eryptosis is stimulated by oxidative stress, activated complement, hyperosmotic shock, energy depletion, cellular K + loss, hyperthermia, ultraviolet illumination and c-irradiation [4,28,101,102]. In the following sections, a detailed discussion is provided on various systemic conditions, which are associated with enhanced eryptosis mediated by multiple sources of ROS linked to the pathophysiology of these conditions.
Oxidative stress and eryptosis in iron deficiency
Iron deficiency (ID) is the most common type of anemia, affecting 500-600 million people worldwide [103, 104] . Underlying causes for a lack of iron may include impaired iron absorption, loss of iron or chronic bleeding leading to insufficient erythrocyte production. The anemia is, however, not only the result of an impaired erythropoiesis, but may be also due to a shortened lifespan of iron-deficient erythrocytes due to eryptosis [104] . A study by Kempe et al.
showed that PS-exposure of erythrocytes increased from 2.4 to 3.7% in mice under iron-deficient diet as compared to mice on control diet. Furthermore, patch clamp experiments revealed an increased cation channel activity and an increase of [Ca 2+ ] i in the iron-deficient erythrocytes (2.3 fold) [ (Fig. 3) . Additionally, enzymes including GPx and superoxide dismutase showed lower levels in comparison to healthy controls [105] (Fig. 3) . Another study by Nagababu et al. corroborated the increased oxidative stress in an experimental iron-deficiency mouse model using fluorescence measurements to determine ROS levels and could observe a higher fluorescence intensity in erythrocyte lysates of iron-deficient mice suffering from anemia as compared to the control mice [106] . Taken together, oxidative stress in ID may result from increased production of ROS and a diminished activity of antioxidant defense mechanisms and likely contributes to clearance of the eryptotic erythrocytes and, thus, to anemia.
Oxidative stress and eryptosis in dyslipidemia, hypertension and diabetes Dyslipidemia is an anomalous quantity of circulating lipids, for example, cholesterol or triglycerides, which may result in hyperlipidemia. Arterial hypertension, a condition hallmarked by increased arterial pressure, either diastolic or systolic, is commonly found in dyslipidemic patients. Both arterial hypertension and dyslipidemia are known to generate oxidative stress. Accordingly, it was previously shown that hypertensive and/or dyslipidemic individuals had 30% lower GSH levels and a doubling of mean lipid peroxidation than normotensive patients without dyslipidemia [107] (Fig. 3) 2+ entry, suggesting that mechanisms other than oxidative stress may contribute to the triggering of eryptosis in that disease [107] . In fact, PS-exposure and thus, eryptosis rate, was three times higher in dyslipidemic normotensive patients than in healthy controls and 2.3 times augmented in dyslipidemic hypertensive patients as compared to dyslipidemic normotensive individuals [107] . In addition, studies in C57/BL6 mice provide further evidence on the effect of changes in lipid profile, triggered by a high-fat diet (HFD), on increased PS-exposure and enhanced levels of oxidative stress determined by 2, 7 0 -dichlorodihydrofluorescein diacetate (DCFDA). As clearance of erythrocytes is executed by macrophage phagocytosis, an approximately 1.4-fold increase in phagocytosis of HFD-erythrocytes was detected in comparison to control-diet (CD)-erythrocytes [111] . A particularly important indicator of eryptosis in vivo is the spleen size as the spleen is the major organ responsible for the removal of eryptotic erythrocytes. Splenic uptake of HDF-erythrocytes was commensurately increased (approximately 3-fold) as compared to CDerythrocytes [111] , strongly supporting the observations of higher eryptosis rate detected in vitro.
Additionally, oxidative stress seems to be involved in the vicious circle of insulin resistance, b-cell malfunction, glucose intolerance and pre-existing conditions that may all result in the development of type 2 diabetes mellitus (T2DM) [112] . Diabetes mellitus is a group of metabolic disorders hallmarked by enhanced blood glucose levels (hyperglycemia) and deficit in the action and generation of insulin supplied by the pancreas [113] . Long-standing increase in blood glucose levels is affiliated with vascular complications, which may enhance the risk of stroke, heart and kidney diseases [114] . Besides hyperglycemia, hyperlipidemia and oxidative stress also contribute to the pathogenesis of T2DM [65] . Oxidative stress and free radicals are assumed to play an essential role in the development of complications in T2DM comprising nephropathy, coronary artery disease, retinopathy and neuropathy [115] . Accumulating evidence points to oxidative stress in T2DM resulting from a variety of pathophysiological alterations such as inflammation, hyperglycemia, dyslipidemia and insulin resistance [116] . Sources of ROS in T2DM may encompass reduced tissue levels of antioxidants such as vitamin E and reduced GSH, diminished activities of catalase and superoxide dismutase, shifts in redox balances, auto-oxidation of glucose, glycation of antioxidative enzymes and glycated proteins [117] . Compelling evidence suggests that the enhanced intra-and extracellular glucose levels may additionally cause oxidative stress [118] . Furthermore, ROS in T2DM are produced in endothelial cells by xanthine oxidases, nicotinamide dinucleotide phosphate (NADPH) oxidases, endothelial NO synthases (NOS), mitochondria and cyclooxygenases (COXs) (Fig. 3) [119]. According to a previous study, a significant correlation was observed between deficiency of GPx as well as glutathione reductase and a low hemoglobin concentration, thus, implicating oxidative stress as a possible cause of anemia in T2DM patients [120] . The anemia is prevalent in 14-45% of the patients and may in part result from an abnormal morphology of the erythrocytes leading to enhanced eryptosis in DM [121, 122] . The anemia in DM can be not attributed to a decreased formation of erythrocytes as reticulocyte number in DM was increased, but rather to an increased destruction of the erythrocytes as PS-exposure was significantly increased in the DM patients. Accordingly, a significant correlation was observed between the number of eryptotic erythrocytes and reticulocytes [122] . Oxidative stress within the erythrocytes of DM patients was determined by DCFDAfluorescence and was significantly augmented, thus, possibly contributing to enhanced exposure of PS from the inner leaflet of the membrane to its outer surface in that condition [122] .
Oxidative stress and eryptosis in heart failure
Heart failure (HF) is one of the most prevalent manifestations of cardiovascular diseases affecting 23 million people globally [123] . Anemia is a frequent comorbidity of HF and negatively influences its clinical outcome [124] . About 55.6% of HF patients have hemoglobin levels lower than 12 gÁdL À1 [125] . While ID has been widely implicated to cause anemia in HF, the anemia in a considerable number of patients is, however, refractory to treatment [126] . Although different components have been proposed to contribute to HF-associated anemia, the precise pathophysiology remains unclear.
Recent evidence suggests that enhanced death of erythrocytes contributes to anemia in HF [126] . In a study by Attanasio et al., the percentage of PS-exposing erythrocytes was significantly higher in HF patients (1.8 AE 0.1%) as compared to the healthy control group (1.2 AE 0.2%). The increased eryptosis in these patients was accompanied by increased production of ROS [126] , which are known to be enhanced in HF [61] . Another study in five patients and a rat model suffering from HF provides further evidence that eryptosis may be a possible source contributing to anemia in that disease that has been missed out so far [127] . The rat model in that study involved REN2 rats developing HF and Sprague-Dawley (SD) rats as a control group. REN2 rats showed significantly higher oxidative stress levels, which were shown to lead to increased cytosolic [Ca 2+ ] i and, thus, to an augmented scrambling of cell membrane phospholipids, which was about twofold higher in the REN2 rats as compared to the control rats [127] . The REN2 rats furthermore displayed splenomegaly and erythrocytes of these rats were cleared faster from the circulating blood, typical indicators of eryptosis. Although mice that underwent transverse aortic constriction (TAC) and developed HF did not show a higher spontaneous eryptosis rate as compared to control mice, cell membrane scrambling in these mice was similarly augmented in response to treatment of erythrocytes with oxidative stress [127] . Sources of ROS in the failing heart comprise endothelial cells, neutrophils and cardiac myocytes [61] (Fig. 3) . ROS are released from a variety of intracellular stores including NAD(P)H oxidase, uncoupled nitric oxide synthase, xanthine oxidase and mitochondria [61] and may potentially affect erythrocyte survival, thus contributing to eryptosis in HF [126] .
Oxidative stress and eryptosis in chronic kidney disease Cardiovascular complications are not only the main cause of mortality in the general population, but also in patients with chronic kidney disease (CKD) [ [135, 136] . However, oxidant species can also directly cause renal ischemia and glomerular damage contributing to the progression of CKD [137] . Hemodialysis (HD) itself also increases oxidative stress by activation of the complement pathway and stimulation of inflammatory processes (Fig. 4) [138]. Oxidative stress during HD is generated by the dialysis membrane itself and is further aggravated by a loss of antioxidant vitamins during this process [129] . The kidney is able to produce several antioxidant enzymes. If this function is, however, impaired dysfunction of erythrocyte membrane, increased hemolysis and decreased platelet functions may ensue [139] . Similarly, oxidative stress within the erythrocyte is increased in CKD, leading to enhanced suicidal erythrocyte death in end-stage renal disease (ESRD) patients (0.84 AE 0.09%) as compared to the healthy controls (0.43 AE 0.04%) and was further enhanced after HD (1.35 AE 0.13%) [52] . The results indicate that HD itself has a damaging effect on erythrocytes leading to their reduced survival in the blood stream [140] . Not only in HD patients but also in peritoneal dialysis (PD) patients, oxidative stress has been shown to be augmented leading to a doubling in the percentage of circulating eryptotic erythrocytes [141] . Notably, both HD and PD patients, despite receiving higher doses of erythropoietin (3125 I.U. ESA in HD and 4583 I.U. ESA in PD), remained anemic with hemoglobin levels of 10.07 gÁdL À1 (HD) and 10.89 gÁdL À1 (PD), indicating that anemia is a major complication in CKD [141, 142] . Mounting evidence for a decreased erythrocyte survival in CKD is provided by additional studies [51, 53] . Thus, these observations indicate that anemia in ESRD is, in large part, due to accelerated clearance of circulating erythrocytes in the blood stream resulting from increased stimulation of eryptosis and remains refractory to therapeutic overcompensation of erythropoietin deficiency [51, 143] .
Oxidative stress and eryptosis in malaria
Malaria is a mosquito-borne infectious disease affecting 300-500 million people globally every year [144] . Infection with Plasmodium falciparum is the most virulent form and accounts for the majority of the malaria-associated morbidity and mortality [145] . P. falciparum infections can be asymptomatic but can also lead to the classical form of malaria causing fever, cerebral malaria and severe malarial anemia (SMA) with hemoglobin levels of lower than 5 gÁdL À1 [145, 146] . SMA arises during the blood stage of infection and accounts for one-third of deaths caused by the falciparum species [147] . Anemia in malaria has different etiologies and may be due to a diminished generation of erythrocytes in the bone marrow that is exacerbated by rapid elimination of circulating erythrocytes from the blood circulation due to extravascular hemolysis of erythrocytes [148] . One crucial factor in the development of anemia is the production of ROS that are produced both outside and within the infected erythrocyte. Inside the cell, the parasite uses the host's molecule as a source of amino acids leading to hemoglobin degradation and release of large amounts of toxic free heme and ROS [149] . Indeed, Plasmodium-infected erythrocytes produce double the amount of H 2 O 2 and OHÁ than normal erythrocytes [149] . Likewise, as part of the host defense mechanism, neutrophils and macrophages are activated and produce enormous amounts of RNS and ROS as part of the inflammatory defense (Fig. 4) . As ROS are able to diffuse through the erythrocyte membrane, they not only harm the parasite but also the erythrocyte [150] . Thus, it seems obvious that P. falciparum infected erythrocytes undergo eryptosis, as it has been discussed in various studies in the past [88, 151, 152] . Several drugs used in the treatment of malaria, for example, artesunate effectively kill intraerythrocytic parasites by partially inducing oxidative stress [153] . In fact, treatment of erythrocytes with artesunate has been shown to increase ROS production and causes eryptosis [154] . The production of oxidant species is, thus, a double edged sword, as it eliminates, on the one hand, the parasite, but, on the other hand, triggers suicidal erythrocyte death leading to anemia [99, 155, 156] .
Oxidative stress and eryptosis in malignancy
Several types of cancers have been linked to enhanced ROS production including pancreatic cancer or bladder cancer [157] . Oxidative stress can influence many crucial stages in cancer development [158] . Possible sources of reactive species that may contribute to tumor development include external factors (e.g., smoking) or UV radiation [159] . On top of that, endogenous components may also play an essential role in ROS production and tumor evolution. Chronic inflammation is linked to tumor development [160] , during which a huge amount of ROS are released by leukocytes and mast cells during the 'respiratory burst'. The ROS production is reinforced by the secretion of soluble factors, for example, chemokines and cytokines [161] . ROS production can indirectly or directly lead to tumor development [162] [163] [164] . In a persisting tumor, on the other hand, neutrophils and macrophages produce ROS in order to kill tumor cells, a well known mechanism [165] . Furthermore, cancer cells themselves produce immense amounts of reactive species, for example, due to augmented metabolic activities [166] [167] [168] . Under conditions of oxygen deprivation, some parts of the tumor may become hypoxic. In these hypoxic areas of the tumor, ROS production is even more enhanced promoting tumor adaptation, survival and persistence (Fig. 4) [169] . Taken together, it is likely that all these different sources of reactive species during malignancy contribute to enhanced suicidal erythrocyte death and, thus, to anemia in cancer.
Evidence for this assumption is provided by a study showing that reactive species are also found in increased numbers in the erythrocytes of lung cancer patients without and with chemotherapy [170] . The patients undergoing chemotherapy displayed an even higher ROS production and magnitude of eryptosis causing more severe eryptosis and anemia as compared to patients who did not receive chemotherapy [170] . In fact, eryptosis rate was highest in patients receiving chemotherapy (1.4 AE 0.1%), followed by patients not receiving chemotherapy (1.2 AE 0.3%) and was lowest in the healthy control group (0.6 AE 0.1%) [170] . On top of that, eryptosis and anemia were accompanied by significantly higher reticulocytosis in the group receiving chemotherapy (3.0 AE 0.6%) as compared to the healthy volunteers (1.4 AE 0.2%), pointing to enhanced turnover of erythrocytes in lung cancer [170] . Eryptosis in malignancy may further be stimulated by treatment with chemotherapeutic agents, contributing to deterioration of normal erythrocyte counts in patients [79, 171] . Indeed, many of the currently applied anticancer agents are designed to eliminate cancer cells by induction of ROS [172] . In addition to cytostatic drugs, a wide variety of xenobiotics and endogenous substances stimulate eryptosis. Many of these substances are in part effective by inducing oxidative stress. Additional evidence for eryptosis in cancer is supplied by another study in mice carrying a loss-of-function mutation of the adenomatous polyposis (APC) gene leading to colonic carcinoma. These mice not only displayed signs and symptoms of anemia, but also showed increased eryptosis, a higher reticulocyte count at different ages and an expedited clearance of circulating erythrocytes, as determined by CFSE labeling. Furthermore, splenomegaly was observed in these mice, pointing to an increased erythrocyte turnover as a consequence of enhanced eryptosis [173] .
Oxidative stress and eryptosis in the elderly
Intensification of oxidative stress-induced damage and mitochondrial dysfunction are assumed to play a decisive role in the aging process [174] . Oxidative stress expedites the aging process by mTOR signaling activation, telomere shortening and by triggering DNA damage [175] . Similar to the general population, the oxidative balance in the elderly can be influenced by a variety of endogenous and environmental factors including lifestyle, prescription of drugs, comorbidities, hormonal, psychological, genetic, neurological and immunological components [176] . Increased production of ROS in the elderly may be the result of a diminished antioxidant capacity, impaired repair mechanisms and an augmentation of oxidized molecules [177] (Fig. 4) . Epidemiological studies confirm that one-third of elderly people suffers from anemia of unknown origin [178] . In fact, more than 50% of the individuals above 80 years of age suffer from anemia [179] . Anemia is not only accompanied by a reduced quality of life, but also by increased morbidity and mortality [180] . Although several hypotheses, for example, a decreased production of erythropoietin or an insufficient response to EPO, have been proposed, none of these hypotheses could have been satisfactorily resolved by experimental evidence [178] . In a study by Lupescu et al., the authors proposed that eryptosis contributes to anemia as elderly people (88.6 AE 0.9 years) showed almost a doubling of cell membrane scrambling erythrocytes (2.5 AE 0.2%) as compared to the young volunteers (1.3 AE 0.1%; mean age: 31.3 AE 1.7 years). The enhanced eryptosis was accompanied not only by an enhanced ROS production within the erythrocytes, but also by a decreased GSH content, measured by mercury orange fluorescence. Additionally, the elderly people displayed enhanced reticulocytosis (2.3 AE 0.2% vs 0.9 AE 0.1% in the control group), which significantly correlated with hemoglobin level [181] . Eryptosis may thus, at least partially, explain the prevailing anemia in the elderly cohort [80, 181, 182] .
Oxidative stress and eryptosis in liver disease
The liver is the main detoxifying organ and is responsible for metabolic homeostasis. The inability of the liver to fulfill its normal physiological function can result in acute or chronic hepatic failure. Acute hepatic failure (AHF) is hallmarked by a rapid and immense necrosis and hepatocyte apoptosis [183] . Underlying causes of AHF are mainly drug-induced liver toxicity [184] or viral hepatitis [185] . In chronic liver disease (CLD), liver parenchyma is progressively destroyed leading to liver fibrosis and cirrhosis. Main causes of CLD are alcohol abuse, hepatitis or nonalcoholic fatty liver disease [186, 187] .
The liver is an organ of high metabolic activity, and thus, an essential place for production of free radicals [188] . CLDs are almost always characterized by augmented oxidative stress, regardless of their preliminary underlying cause [189] . Oxidative stress not only damages cellular components like DNA, proteins or lipids, but also causes the release of proinflammatory cytokines leading to hepatic fibrosis, inflammation and cirrhosis [190] . The dying hepatocytes are also a source of oxidative stress causing further destruction of hepatocytes and release of ROS, thus, establishing a vicious circle [183] . In the various forms of liver disease, ROS are mainly produced in the mitochondria and endoplasmic reticulum by cytochrome P450 enzymes, a process occurring in hepatocytes, Kupffer cells and neutrophils (Fig. 5) [191] . In the course of liver disease, anemia can arise due to vitamin deficiency, cancer, infection, blood loss, alcohol intoxication or infection [192] . In fact, in 75% of the cases of CLDs hematological aberrations occur [193] . In a study by Lang et al. [194] , it has been proposed that accelerated suicidal death of erythrocytes contributes to anemia in hyperbilirubinemic patients with hepatic failure. In that study, the authors provide evidence that the enhanced bilirubin concentrations present during liver disease are a main trigger of eryptosis and anemia observed in vivo and in vitro; PS-exposure of the erythrocytes significantly correlated with plasma bilirubin levels and inversely correlated with erythrocyte number of the patients [194] . Additionally, the authors utilized a mouse model, in which bile duct ligation (BDL) was performed leading to progressive hepatic failure. The BDL mice exhibited increased suicidal erythrocyte death and their erythrocytes were cleared faster from the circulating blood stream, indicating enhanced erythrocyte turnover in these mice that are typical signs of eryptosis [194] . Bilirubin levels correlated negatively with hemoglobin levels and erythrocyte number, but correlated positively with reticulocyte numbers, suggesting that bilirubin triggers anemia and, thus, a subsequent formation of new erythrocytes in these mice [194] . Given the fact that oxidative stress in CLD is enhanced, oxidative stress may additionally trigger accelerated suicidal death in that condition. Therefore, further investigation in this area could be highly relevant to better understand the role of oxidative stress 
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Enhanced eryptosis is, similarly, augmented in Wilson 0 s disease [195] , a rare autosomal recessive genetic disorder of copper metabolism, in which excess copper accumulates in different organs including the liver [196] . Occasionally, Wilson 0 s disease leads to anemia [197] . Copper itself is known to trigger release of oxidant species, which play a crucial role in the induction of cell death by copper [198] . Lysosomes and mitochondria treated with Cu 2+ have been demonstrated to release an immense amount of ROS [199, 200] . In erythrocytes, treatment with Cu 2+ leads to inhibition of antioxidant enzymes and formation of lipid peroxides and, thus, to oxidative stress formation. Finally, damage of the cell due to oxidative stress occurs and leads to denaturation of hemoglobin and occasionally to Heinz body formation which are intraerythrocytic inclusions containing denatured hemoglobin [201] . This oxidative denaturation of hemoglobin subsequently leads to erythrocyte senescence and their subsequent destruction [202] . Accordingly, suicidal erythrocyte death has been extensively shown to occur in Wilson 0 s disease. Proofs for eryptosis and its underlying mechanism in Wilson 0 s disease has not only been provided in human individuals but also in a mouse and rat model [195] .
Oxidative stress and eryptosis in inflammation and autoimmune diseases
Arteritis is a disease causing inflammation of the vascular wall giving rise to vascular occlusions and ischemia and is typically the result of an autoimmune response or an infection. Arteritis may involve medium and large-sized arteries throughout the whole body and may be accompanied by anemia of varying severity [203] . In vascular abnormalities, oxidative stress is a general and fundamental feature of the inflammatory process and is uniformly harmful in these conditions [204] . At the site of inflammation, polymorphonuclear neutrophils (PMNs), macrophages and lymphocytes produce a high amount of ROS leading to tissue damage and endothelial dysfunction [205] (Fig. 5) . As enhanced ROS production in inflammatory diseases may impair erythrocyte survival, typical signs of eryptosis have been analyzed in a previous study involving 17 patients suffering from arteritis. In fact, arteritis patients showed decreased erythrocyte number, hemoglobin and hematocrit levels despite increased formation of reticulocytes [206] . The percentage of PS-exposing cells, analyzed by flow cytometry, was more than 3-fold higher in the patient cohort (1.1 AE 0.1%) as compared to the healthy control group (0.3 AE 0.1%). Increased PS-exposure in the patient group was confirmed by confocal imaging. The increased cell membrane scrambling was accompanied by enhanced cytosolic Ca 2+ levels and oxidative stress [206] . On top of that, a study by Bester & Pretorius [207] recently showed that different cytokines influence erythrocyte structure and induced changes in their morphology, similar to the alterations that can be seen during eryptosis. Another study by Silva-Herdade et al. [208] showed that erythrocytes undergo deformabilities in the presence of inflammatory stress. A variety of proinflammatory molecules (for example, ROS) have the potential to promote the synthesis and secretion of such proinflammatory cytokines [209] . Stimulated eryptosis in arteritis may, thus, be the result of enhanced ROS and cytokine production [206] . In addition, cytokines are known to modulate the expression of storage proteins and iron transport [210] . As inflammation is often accompanied by hypoferremia [211] , cytokine production may be involved in hypoferremia and subsequent development of anemia. In a study by Nemeth et al., the authors have established an important correlation between inflammation, cytokine production and hepcidin, an iron regulatory hormone [212] . Upon IL-6 stimulation, hepcidin production in the hepatocytes is augmented and functions as a negative regulator of iron absorption from the intestine, triggering hypoferremia [213] . As hypoferremia causes anemia, the cytokine-hepcidin interaction appears to be another important mediator of inflammation-related anemia.
Another autoimmune disease, showing an inflammatory etiopathology, is systemic lupus erythematosus (SLE). In SLE, a variety of autoantibodies are produced which are directed against nuclear components, for example, double-stranded DNA (dsDNA) or chromatin. The resulting autoantibody mediated immune complexes are deposited in several organs, thus, leading to tissue damage and subsequent inflammation [214] . In SLE patients, ROS are mostly derived from the mitochondria of vascular endothelial cells and lymphocytes and are involved in the pathogenesis of SLE [215] . Additionally, ROS can be generated by NADPH oxidase in lysosomes and microsomes [216] , polymononuclear cells and phagocytic cells (Fig. 5 ) [217] [218] [219] . Moreover, reduced intracellular GSH levels and increased ROS levels were found in different blood components in SLE patients [220, 221] . As increased ROS levels are abundant in SLE and could trigger eryptosis, Jiang et al. performed a study in SLE patients examining eryptosis-related parameters such as PS exposure, cytosolic Ca 2+ concentration, ROS and ceramide abundance. As a result, they found a higher PS-exposure in the SLE patients (4.1 AE 0.24%) than in the healthy volunteers (2.5 AE 0.19%), which was accompanied by higher levels of [Ca 2+ ] i and oxidative stress (measured by DCF fluorescence). Ceramide abundance tended to be higher in fresh erythrocytes of the SLE patients, the difference did, however, not reach statistical significance [222] . As the majority of SLE patients suffer from anemia, especially in the later stages of the disease [223] , inhibition of eryptosis could, thus, diminish anemia in these patients and should be taken into consideration as a possible treatment strategy.
Oxidative stress and eryptosis in various blood disorders
Sickle cell disease (SCD) is an inherited blood disorder characterized by repeated infections, periodic pain episodes and anemia. In SCD, erythrocytes contain sickle hemoglobin (HbS) instead of normal hemoglobin (HbA). Under certain circumstances, the erythrocytes become inflexible, rigid and acquire a sickle-like shape. SCD is characterized by chronic hemolytic anemia and vaso-occlusive events [224] . Oxidative stress is ascribed an important role in the pathophysiology of SCD and can arise from different origins and sources in that condition. HbS, for example, is able to bind to the erythrocyte membrane and can act as a Fenton reagent, which augments the production of hydroxyl radicals (OHÁ), H 2 O 2 and superoxide anions (O À 2 ), leading to membrane damage [225, 226] (Fig. 6) . The production of these oxidants have been reported to be twofold higher in SCD erythrocytes than in normal erythrocytes [227, 228] . A further study has reported an even 10 to 30 fold higher ROS formation and a 20-50% lower GSH concentration in platelets, PMNs and erythrocytes of SCD patients [229] . Another cause of oxidative stress in SCD is the elevated iron content and iron is known to catalyze ROS production [230] (Fig. 6) . As oxidative stress is a major trigger of eryptosis, SCD erythrocytes display an increased apoptotic death than normal erythrocytes as measured by a higher PS-exposure in SCD (9.4 AE 1.2% vs 3.0 AE 1.2% in the healthy control group) [231] . Additionally, PS-exposure was higher in SCD erythrocytes after a 24 h incubation in isotonic Ringer solution (14.9 AE 3.0% vs 3.9 AE 0.7% in the control group). SCD erythrocytes displayed an increased sensitivity to oxidative stress, triggered by in vitro exposure to 1 mM tert-butyl-hydroperoxide (tBOOH), resulting in an increased number of apoptotic cells [231] . Inhibition of ROS production in SCD would be, thus, an important target for an antioxidant therapy in that disease [232] , which not only diminishes anemia but also lowers the risk for vaso-occlusive events that affects several organ systems, for example, brain, lung, liver, joint, bones and spleen [224] . b-thalassemia comprises a heterogeneous group of blood disorders hallmarked by the diminished or the absence of synthesis of the b-globin chain of hemoglobin. In the homozygous state of the disease, b-thalassemia leads to transfusion-dependent anemia which may be milder in the heterozygous state. Due to mutations, the expression of the b-globin gene is affected [233] leading to excess of unpaired a-globin chains, which are a primary cause for oxidative stress and iron excess in that disease [234] (Fig. 6) . The iron overload, in turn, promotes the generation of free radicals [233] . Within the erythrocytes, higher amounts of reactive oxygen intermediates, for example, hydrogen peroxide, superoxide anion and hydroxyl radicals have been detected [234] (Fig. 6) . Moreover, total antioxidant capacity and vitamin E levels in the serum of affected individuals were reduced. Similar to sickle cell erythrocytes, erythrocytes of b-thalassemic patients show a higher PS-exposing rate on their surface (3.32 AE 0.45%) as compared to healthy volunteers (1.78 AE 0.07%) [235] . Similar observations were made in another study, where PS-exposure tended to be higher in the b-thalassemic cohort (5.8 AE 2.6% vs. 3.0 AE 1.2% in the control group) although the difference did not reach statistical significance [231] .
Taken together, a reduced antioxidant defense, and oxidative stress as well as eryptosis play a major role in the pathogenesis of b-thalassemia and may contribute to the shortened survival of erythrocytes in that disease [231, 234] .
Hereditary spherocytosis (HS) is a hereditable blood disease that belongs to the congenital anemia and affects erythrocyte membrane proteins leading to sphere-shaped cells [236] . The abnormalities in the shape are responsible for the fragility of the erythrocytes and cause rupture of the cells [237] . Band3, ankyrin, spectrin and protein 4.2 are the most frequently affected membrane proteins [238, 239] . The severity of HS may range from asymptomatic patients to patients who require regular blood transfusion from early childhood [236] . In this disease, the erythrocytes themselves play an important role in the generation of not only ROS but also membrane lipid peroxide while showing impaired production of reduced GSH [240] (Fig. 6) . The enhanced oxidative stress levels in HS can be addressed by higher methemoglobin formation and hemoglobin auto-oxidation [241] (Fig. 6) . Consequently, the occurrence of eryptosis in HS is likely and has been accordingly explored in a study by Crisp et al. [242] . Interestingly, eryptosis in HS seems to be temperature dependent as both PS-exposure and cell shrinkage in HS patients increase strongly with increasing temperature from 36.5°C to 38.5°C. Similarly, intracellular Ca 2+ content in HS patients is highest at 38.5°C. At any temperature, eryptosis of HS erythrocytes was higher as compared to normal erythrocytes [242] . Surprisingly, Crisp et al. [242] could not observe any differences in ROS and GSH content either between or within the groups. Nevertheless, independent of the underlying mechanism, eryptosis seems to occur in HS and, thus, likely contributes to HS-associated anemia.
Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic and rare disease of the blood, which frequently appears in early adulthood. The development of thrombosis, diminished bone marrow function and increased erythrocyte destruction by hemolysis are known hallmarks of the disease [243] . The severity of inadequate erythropoietic activity and intravascular hemolysis may differ from patient to patient [243] . Previous studies have reported that thrombosis is the most frequent and feared complication of PNH [244] . Oxidative stress strongly contributes to the pathogenesis of PNH and leads to the activation of platelets, which may subsequently lead to thrombotic complications in this disease [245] . Oxidative stress levels in PNH patients were shown to be increased in RBCs, PMNs and platelets, accompanied by higher membrane lipid peroxidation and lower GSH levels [245] . Concerning the formation of ROS in PNH, different sources of ROS have been reported in the literature. One study provided evidence that the increased oxidative stress of blood cells in PNH patients may result from the cellular abnormalities caused by the PNH defect, for example, by lack or diminished expression of CD59, a membrane component [246] (Fig. 6) . In fact, ROS formation was stimulated after blocking surface CD59 in their study [246] . Oxidative stress may then activate complement system, probably by hydrogen peroxide radicals [247] . On the other hand, complement activation induces oxidative stress in PNH cells, thus, establishing a vicious cycle [248] (Fig. 6) . As anemia and the occurrence of thrombotic complications may at least in part be explained by enhanced eryptosis, Basu et al. [249] investigated the survival propensity of erythrocytes from PNH patients by measurement of the extent of PS exposing cells and cell surface glycophorin levels. For this purpose, they fractioned the total erythrocyte number into lighter and heavier populations. As a result, they could observe that in normal individuals, the heavier cellular fraction of the aged erythrocytes exposed significantly higher amount of PS than the younger erythrocytes; in the PNH individuals this trend was, however, reversed. Furthermore, decreased erythrocyte lifespan correlated with the loss of glycophorin from the erythrocyte surface in PNH [249] . The observations on increased eryptosis in PNH may explain the shortened lifespan of erythrocytes from PNH patients due to eryptosis and the occurrence of anemia in that disease, which is further exacerbated by hemolysis of the erythrocytes.
Myelodysplastic syndrome patients suffer from anemia due to ineffective hematopoiesis primarily due to impairment in the erythroid precursors. Apparently, the anemia in these patients may be due not only to defects in erythropoiesis but may be also due to an insufficient response to endogenous erythropoietin [180, 250] . Consequently, these patients require blood transfusions and often develop iron overload, a common side effect of transfusions [251] . An oversupply of free iron gives rise to production of ROS by the Haber-Weiss reaction inducing tissue and cell damage [252] (Fig. 6) . In this way, apoptosis may not be only induced in hematopoietic progenitor cells, but also in mature erythrocytes and, thus, eryptosis was explored in a study by Basu et al. in six MDS patients [249] . Similar to PNH, erythrocytes of MDS patients were fractionated into heavier and lighter populations and subsequently, PS-exposure and cell surface glycophorins have been determined. In the cohort of MDS patients, the same observations were made as in the PNH patients, that is, an increased amount of PS-exposing cells in the lighter or younger erythrocytes and a comparatively opposite trend in the healthy control group. Similar to PNH, increased loss of glycophorin in the MDS patients as compared to the control group has been found [249] . From these observations, it can be concluded that eryptosis should deserve attention in PNH and MDS-related anemia.
Mounting evidence suggests that oxidative stress is similarly enhanced in hemolytic uremic syndrome (HUS), a disease characterized by variable organ damage and hemolytic anemia [253, 254] . HUS can occur due to infection with enterohemorrhagic strains of Escherichia coli-producing Shiga toxin and its interaction with the vascular endothelium (classical HUS) [255] . A study by Ferraris et al. reported significantly higher levels of plasma lipid peroxidation, measured by thiobarbituric acid-reactive substances (TBARs) in HUS individuals, pointing to increased oxidative stress in that condition (Fig. 6) . Additionally, Shiga toxin itself contributes to pathophysiology of HUS by induction of oxidative stress [256] (Fig. 6) . As oxidative stress is a main trigger of eryptosis, a previous study investigated a possible role of suicidal erythrocyte death contributing to anemia in HUS. As a result, it was shown that HUS individuals suffered from enhanced death of erythrocytes and individuals lacking complement inactivating factor H were predisposed to the development of HUS [254] . PS-exposure of erythrocytes from HUS patients was significantly augmented before (1.03 AE 0.18%) than after plasmapheresis (0.49 AE 0.18%), indicating that a plasma component triggered eryptosis in HUS. Finally, complement activation was identified as possible mechanism triggering enhanced cell membrane scrambling and eryptosis in HUS [254] . It is known that the complement system plays a decisive role in mediating tissue injury following oxidative stress and that oxidative stress leads to stimulation and deposition of complement on the vascular endothelium [257] . Further investigation would, however, be required to study the exact interplay between oxidative stress and complement system and its influence on suicidal erythrocyte death in HUS.
Pharmacological inhibition of oxidative stress in erythrocytes in vitro and in vivo
To the extent that stimulated eryptosis may lead to anemia and thrombosis, it may be desirable to inhibit eryptosis. As a matter of fact, a wide variety of compounds such as blebbistatin, phlorhizin, vitamin C, resveratrol, reversine, hydroxytyrosol, volasertib, ASP3026 and teriflunomide have previously been shown to inhibit eryptosis in vitro [258] [259] [260] [261] [262] [263] [264] [265] [266] [267] . Some of these substances have previously been shown to counteract oxidative stress and may potentially be effective in vivo and could, therefore, be considered for the treatment of eryptosis-induced anemia in different clinical conditions. Table 1 summarizes common antioxidants previously shown to influence erythrocyte integrity and survival in vivo.
Antioxidants prevent the production of free radicals by avoiding their accumulation and, thus, ameliorate oxidative stress generation [245] . They can be grouped into natural antioxidants (e.g., vitamins C and A), endogenous antioxidants (e.g., bilirubin, alpha-lipoic acid, melatonin) and synthetic antioxidants (e.g., N-acetylcysteine (NAC), selenium, pyruvate) [159] . The major scavenger of oxidative stress in erythrocytes is GSH. Glutamate-cysteine ligase, which partly consists of a modifier subunit (GCLM), is crucial for GSH synthesis and rate-limiting [268] . The importance of GSH in erythrocyte survival has been shown in an in vivo study by Foller et al. 2013 . In that study, erythrocytes deficient of the modifier subunit GCLM of glutamate cysteine-ligase (gclm
), showed a significantly higher amount of exposed phosphatidylserine on their membrane surface upon incubation to oxidative stress as compared to gclm +/+ erythrocytes. Increased eryptosis was accompanied by reticulocytosis in vivo, probably as a response to the increased loss of erythrocytes due to eryptosis [269] . The study, thus, proved that GCLM is inalienable for erythrocyte survival.
In a rat model of HF, the antioxidant thymol has been shown to counteract anemia by enhancing hematocrit levels [127] . An underlying mechanism in that condition may be a diminished eryptosis after application of thymol and, as a result, a diminished loss of erythrocytes by eryptosis. Previously, thymol has been shown to inhibit apoptotic death in erythrocytes [270] . The antioxidant capacity of thymol has been proven in vivo in male rats [271] and weaning piglets [272] . On top of that, studies in HF patients report that treatment with erythropoietin does not improve clinical outcome and even enhances the risk of thromboembolic events [124, 273] . As anemia is associated with a worse prognosis in HF patients [274] , treatment of anemia with inhibitors of eryptosis could be beneficial to these patients and may decrease the morbidity and mortality that is linked to anemia in that disease. In mice suffering from liver failure, thymol has been shown to diminish lipid peroxidation, and reduce hepatic injury caused by oxidative stress in that mice [275] . As eryptosis is increased in hepatic failure [195] , thymol could be used as a potent antioxidant therapy in that condition. In diabetes, thymol protects erythrocytes from hemolysis induced by 2,2-azo-bis(2-amidinopropane) dihydrochloride by its activity as a free radical scavenger [276] . As diabetes induces eryptosis [122] , thymol could be used as a pharmacological inhibitor in that disease.
In a further study, murine erythrocytes were incubated with NAC and subsequently labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE), following which these erythrocytes were injected into healthy mice. As a result, the intravenously injected erythrocytes pretreated with NAC showed a significantly higher half-life as compared to untreated erythrocytes [277] . In another study, SCD patients treated with either 1200 or 2400 mg NAC daily for a period of 6 weeks, showed increased whole blood GSH levels, diminished erythrocyte PS-exposure and lower cell-free hemoglobin levels suggesting that the antioxidant treatment counteracts pathological changes in erythrocytes associated with this disease [278] .
The application of antioxidants may have a similar beneficial effect in CKD. A previous study by Shimizu et al. [279] has reported a higher glomerular filtration rate, diminished oxidative stress, and a higher weight gain in rats that underwent a 5/6 nephrectomy and were treated with the antioxidant NAC as compared to untreated rats that underwent this procedure. NAC has been shown to be effective against eryptosis in vitro [280] . Increased eryptosis in CKD mediates enhanced adhesion of erythrocytes to the vascular endothelium which, in turn, could impede microcirculation [281] . Interestingly, administration of the antioxidant resveratrol was shown to significantly improve renal microcirculation in sepsis-induced kidney injury Rate of hemolysis [290] and enhance the overall survival of these mice [282] , which may potentially be mediated by the antieryptotic effect of this compound [79] . In a previous study in a mouse model of b-thalassemia, administration of resveratrol was reported to reduce ineffective erythropoiesis, reticulocyte count and oxidative stress and increase hemoglobin levels and erythrocyte survival pointing to its possible use as therapeutic agent in this disease [283] . In rats suffering from diabetic retinopathy, resveratrol increased superoxide dismutase activity while diminishing weight loss, increased blood glucose and HbA1c levels [284] . As resveratrol also inhibits eryptosis [285] , the observed protective effects of resveratrol in sepsis-induced kidney injury and b-thalassemia may be, at least in part, attributed to attenuated eryptosis. In SCD erythrocytes, vitamins E and C, as well as NAC have been shown to reduce oxidative stress [229] . Accordingly, the authors concluded that the increased ROS formation may in large part account for the clinical manifestations of SCD, including vaso-occlusive events and hemolysis and could be, thus, ameliorated by application of antioxidant therapy [229] . Antioxidant therapy in SCD would, thus, have the potential to reduce the strong anemia prevalent in SCD by inhibition of eryptosis. Vitamin C [286] and NAC [280] have already been shown to inhibit eryptosis in vitro [287] . Besides, vitamin C inhibits eryptosis in glucose-6-phosphate-dehydrogenase deficiency [260] .
In MDS, iron oversupply is one of the main causes of ROS production and, thus, iron chelators, for example, deferiprone or desferrioxamine, are used in the treatment of these patients [252] . Iron chelation therapy or the application of antioxidants not only decrease ROS production but further attenuate injury to the endocrine glands, liver and heart caused by iron overload [252] . On top of that, iron chelators may diminish eryptosis observed in that condition by inhibiting ROS formation [249] .
In hereditary spherocytosis, in vitro incubation of erythrocytes with a fermentation bioproduct of Carica papaya (fermented papaya preparation-FPP), a known antioxidative product, robustly reduced oxidative stress markers [240] . In addition, patients suffering from hereditary spherocytosis treated with FPP for 3 months displayed decreased reticulocyte counts and enhanced hemoglobin levels as compared to nontreated patients [240] . As levels of malonyldialdehyde, an end product of membrane lipid peroxidation, were similarly decreased following FPP treatment, the authors concluded that the observed effects may be attributed to an amelioration of oxidative stress due to administration of FPP [240] . In a further patient study, patients with b-thalassemia major and b-thalassemia intermedia were enrolled and were treated with FPP. After 3 months of treatment with FPP, both groups showed decreased ROS production and membrane lipid peroxidation as well as a reduced erythrocyte PS-exposure. Concomitantly, levels of reduced GSH were elevated following FPP treatment. The authors, however, did not observe any significant changes in other hematological parameters [288] . These observations were corroborated by a further study showing reduced GSH content and ROS in b-thalassemic mice and patients after FPP administration for 3 months. Remarkably, erythrocyte PS-exposure was similarly decreased after treatment of the mice with FPP [289] . Taken together, these results indicate that FPP diminishes oxidative stress in thalassemia and improves the clinical outcome [289] .
A similar beneficial effect of FPP was observed in prediabetic patients that were subjected to 6 g FPP treatment/day for a period of 14 weeks, following which, the rate of hemolysis was significantly reduced, indicating that FPP intake strengthens the total antioxidant status in these patients [290] .
An important caveat of using antioxidant treatment to mitigate suicidal cell death injured erythrocytes in vivo is the potential risk of elevated cell-free hemoglobin levels due to increased hemolysis. Hemoglobin can be removed either in the blood vessels (intravascular hemolysis) or by phagocytes of the reticuloendothelial system (extravascular hemolysis) [245] . However, hemoglobin may still pass the glomerular filter in the kidneys, which leads to its precipitation in the acid tubular lumen. As a consequence, occlusion of the nephrons may result in kidney injury. Thus, balancing the intracellular oxidant and antioxidant factors in erythrocytes is crucial for maintaining both their integrity and survival in the circulation [269] .
Conclusions
Oxidative stress is a powerful stimulator of eryptosis and contributes to the development of anemia in a variety of clinical conditions. The stimulation of eryptosis may further compromise microcirculation, as eryptotic erythrocytes adhere to the vascular wall. In view of the profound impact of anemia and impaired microcirculation, treatment of affected patients with eryptosis-inhibiting substances, such as several antioxidants, may be desirable. The possibility, however, must be kept in mind that the disruption of eryptosis may enhance hemolysis of defective erythrocytes with subsequent renal injury. Further in vivo studies are, thus, required to elucidate the beneficial and/or untoward effects of antieryptotic treatment in counteracting anemia associated with a wide range of systemic diseases. 
